Galderma is the only truly scaled pure-play dermatology company – and we have been meeting patient needs with superior outcomes for over 40 years.
Our commitment to advancing dermatology for every skin story is grounded in that heritage. Through our investment in innovation, we bring to market transformative technologies and services across the three segments in which we compete: Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology.
Galderma R&D operates as one, global integrated R&D platform with synergies across all our product categories. Our in-house organization is designed to drive efficiency and innovation by leveraging our deep scientific, clinical, medical and regulatory expertise and experience.
Since 2019, Galderma's global team of over 650 R&D professionals has played a pivotal role in securing more than 160 major regulatory approvals. These milestones not only underscore our continued growth but also signal the emergence of exciting new dermatological solutions for consumers and patients. Notably, for Cetaphil® alone, Galderma has conducted over 770 clinical trials involving more than 21,000 participants since 2020, furthering our commitment to advancing sensitive skin research.
Our best-in-class R&D pipeline makes us a partner of choice for academic and industrial research collaboration around the world. These partnerships are integral to our success, providing access to diverse perspectives, a wide range of expertise and cutting-edge technologies across the entire spectrum of dermatology.
Clear priorities for each of our product categories will support us to continue meeting the needs of patients, consumers and healthcare professionals and achieve our ambition of becoming the undisputed category leader in dermatology. We are also continuously assessing strategic opportunities to supplement our pipeline with truly differentiated external assets and innovation.
INNOVATION ACROSS OUR THREE PRODUCT CATEGORIES
INJECTABLE AESTHETICS
In Injectable Aesthetics, we maintain sustainable growth by focusing on premium solutions trusted by healthcare professionals around the world.
Our innovative solutions—including neuromodulators, dermal fillers and biostimulators—address a wide range of aesthetic concerns, from dynamic and static wrinkles to asymmetries and aging skin. We are also developing additional offerings for skin quality treatments, including glow and texture.
A pioneering product, Sculptra® leverages PLLA-SCA technology to stimulate natural collagen production. It was recently approved by the U.S. Food and Drug Administration (FDA) for cheek wrinkles. Another of our premium, flagship injectables, Alluzience® is Europe’s first and only ready-to-use liquid neuromodulator.
We also recently received approval from the U.S. FDA for Restylane® EyelightTM one of our newest hyaluronic acid (HA) fillers. The product uses proprietary NASHA® technology to improve the appearance of undereye hollows. Meanwhile, Canada has approved Restylane SHAYPE™, which is powered by new NASHA HD™ technology, for temporary augmentation of the chin region. This new HA gel is both the firmest on the market, and the closest to that found naturally in the skin.
A key component in our neuromodulator pipeline is RelabotulinumtoxinA, our next-generation, ready-to-use liquid formulation of botulinum toxin type A. Results from Phase IIIb studies in 2023 investigating RelabotulinumtoxinA for the treatment of glabellar lines (‘frown lines’) and lateral canthal lines (‘crow’s feet’) showed significant improvements in both.
DERMATOLOGICAL SKINCARE
Remaining competitive in the consumer segment requires relentless innovation grounded in superior science and recommended by dermatologists.
Cetaphil® is one of our flagship brands, with both a seven-decade legacy of trust and a focus on continuous innovation. Its latest launch, Cetaphil Healthy Renew, is a groundbreaking healthy-aging skincare line that provides consumers with a retinol alternative to fight visible signs of aging effectively. Through innovations such as this, Cetaphil’s product range has expanded to cater to various needs, offering cleansers and moisturizers that combat the five signs of sensitive skin.
Alastin® remains a growth driver, enhancing our Dermatological Skincare portfolio through premium offerings. We have expanded the range internationally, and continue to launch multiple new products in the U.S. Our latest additions provide effective solutions to everyday skin concerns. C-Radical Defense, a Vitamin C formula with Sodium Ascorbate and 14 antioxidants, shields against environmental stressors while preserving elastin. And ReSURFACE Skin Polish® gently rejuvenates rough skin with volcanic minerals and glycolic acid.
THERAPEUTIC DERMATOLOGY
In Therapeutic Dermatology, we spearhead ambitious projects that target unmet needs in strategic therapeutic areas.
A top priority for Galderma is the development of nemolizumab, a first-in-class investigational therapy for atopic dermatitis, prurigo nodularis and chronic kidney disease-associated pruritus. Positive data from four pivotal phase III trials in 2023 demonstrated significant improvements in skin lesions and itch compared to placebo.
In February 2024, the U.S. FDA accepted the Biologics License Applications for nemolizumab for the treatment of prurigo nodularis, and for adolescents and adults with moderate to severe atopic dermatitis. Additionally, it granted Priority Review for the treatment of prurigo nodularis.
Beyond this, we continue to add innovative, premium products to our portfolio. And in recent years, we've continued to enhance our leadership in over-the-counter (OTC), topical and oral acne treatments.
Aklief® remains the only formula in the world that that harnesses the latest and most precise retinoid molecule, trifarotene, to clear and refine acne-prone skin. Recent data we presented on Aklief highlighted the product’s efficacy in reducing atrophic acne scarring and post-inflammatory hyperpigmentation as well as improving patient satisfaction.
We also entered a new acne spot treatment segment with the launch of our differentiated and science-backed technology behind Benzac® and Differin® patches in the treatment of emerging pimples.
